These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 25096997)

  • 1. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
    Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
    Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
    Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
    J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors.
    Cheng Y; Anthony L; Delcher C; Moga DC; Chauhan A; Huang B; Adams V
    Oncologist; 2023 Jun; 28(6):479-485. PubMed ID: 36994847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
    Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D
    World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
    Anthony L; Vinik AI
    Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
    Al-Efraij K; Aljama MA; Kennecke HF
    Cancer Med; 2015 Jun; 4(6):864-70. PubMed ID: 25727756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
    Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.
    Pavel ME; Baudin E; Öberg KE; Hainsworth JD; Voi M; Rouyrre N; Peeters M; Gross DJ; Yao JC
    Ann Oncol; 2017 Jul; 28(7):1569-1575. PubMed ID: 28444114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
    Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
    Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
    Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
    J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
    Kvols LK; Oberg KE; O'Dorisio TM; Mohideen P; de Herder WW; Arnold R; Hu K; Zhang Y; Hughes G; Anthony L; Wiedenmann B
    Endocr Relat Cancer; 2012 Oct; 19(5):657-66. PubMed ID: 22807497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors.
    Strosberg J; Weber J; Feldman M; Goldman J; Almhanna K; Kvols L
    Gastrointest Cancer Res; 2013 May; 6(3):81-5. PubMed ID: 23936548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
    Shen C; Xu Y; Dasari A; Shih YC; Yao JC
    Oncologist; 2016 Mar; 21(3):308-13. PubMed ID: 26911407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.